Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC. (VNDA)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:14pm CEST

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum™ (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum™ MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum™ MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt

For full U.S. Prescribing Information for Fanapt, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
[email protected]

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 21:13:01 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
06/14VANDA PHARMACEUTICALS : Patent Issued for Method and Composition for Treating a ..
AQ
06/13VANDA PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders..
AQ
06/05VANDA PHARMACEUTICALS : Announces Participation at June 2018 Investor Conference..
AQ
06/01VANDA PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Termina..
AQ
06/01VANDA PHARMACEUTICALS : Announces Participation at June 2018 Investor Conference..
PR
05/23VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
05/17VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 43rd Annual Health Care ..
AQ
05/08VANDA PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/07VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 43rd Annual Health Care ..
PR
05/02VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
More news
News from SeekingAlpha
06/19INSTITUTIONAL TOP IDEAS : Great Point Partners 
05/23Vanda's Hetlioz effective in jet lag study 
05/23Premarket analyst action - healthcare 
05/10Vanda Pharmaceuticals (VNDA) Presents At 43rd annual Deutsche Bank Healthcare.. 
05/03HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/03/2018) 
Financials ($)
Sales 2018 192 M
EBIT 2018 -40,7 M
Net income 2018 -16,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 55,09
Capi. / Sales 2018 5,19x
Capi. / Sales 2019 4,27x
Capitalization 995 M
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,7 $
Spread / Average Target 8,2%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Secretary & Treasurer
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.25.66%995
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS3.10%40 566
REGENERON PHARMACEUTICALS-11.70%35 172
GENMAB-3.97%9 557
SAREPTA THERAPEUTICS INC152.21%9 196